adapted to steppe-desert climate extremes one million years ago.

Questions about when early members of the genus adapted to extreme environments like deserts and rainforests have traditionally focused on . Here, we present multidisciplinary evidence from Engaji Nanyori in Tanzania's Oldupai Gorge, revealing that thrived in hyperarid landscapes one million years ago. Using biogeochemical analyses, precise chronometric dating, palaeoclimate simulations, biome modeling, fire history reconstructions, palaeobotanical studies, faunal assemblages, and archeological evidence, we reconstruct an environment dominated by semidesert shrubland.

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.

Association of Rate of Functional Recovery With Therapy Time and Content Among Adults With Acquired Brain Injuries in Inpatient Rehabilitation.

Objective: To examine associations among the time and content of rehabilitation treatment with self-care and mobility functional gain rate for adults with acquired brain injury.

Design: Retrospective cohort study using electronic health record and administrative billing data.

Setting: Inpatient rehabilitation unit at a large, academic medical center.

The North American Repository for Archaeological Isotopes.

Here, we present the North American Repository for Archaeological Isotopes (NARIA), the largest open-access compilation of previously reported isotopic measurements (n = 28,374) from bioarchaeological samples in North America (i.e., Canada, Greenland, Mexico, and the United States of America) covering a time-frame of more than 12,000 years.

Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.

Introduction: While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.

Methods: A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.